Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of "Buy" by Analysts

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have been given a consensus rating of "Buy" by the five research firms that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $56.50.

CELC has been the topic of several recent analyst reports. Needham & Company LLC cut their price target on shares of Celcuity from $74.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, August 15th. Stifel Nicolaus started coverage on shares of Celcuity in a research note on Tuesday, July 1st. They set a "buy" rating and a $30.00 price objective on the stock. Leerink Partners increased their price objective on shares of Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research note on Monday, July 28th. HC Wainwright increased their price objective on shares of Celcuity from $50.00 to $66.00 and gave the stock a "buy" rating in a research note on Monday, August 18th. Finally, Guggenheim initiated coverage on Celcuity in a research report on Monday. They set a "buy" rating on the stock.

Read Our Latest Report on CELC

Celcuity Price Performance

Shares of Celcuity stock opened at $51.88 on Monday. Celcuity has a twelve month low of $7.57 and a twelve month high of $63.06. The stock has a market capitalization of $2.20 billion, a P/E ratio of -15.04 and a beta of 0.72. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 2.24. The business's fifty day moving average price is $42.86 and its 200 day moving average price is $22.13.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.14). As a group, research analysts anticipate that Celcuity will post -2.62 earnings per share for the current year.

Insiders Place Their Bets

In other Celcuity news, Director David Dalvey sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the sale, the director owned 125,000 shares in the company, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 15.78% of the stock is owned by corporate insiders.

Institutional Trading of Celcuity

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its holdings in shares of Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company's stock valued at $570,000 after purchasing an additional 503 shares during the period. Intech Investment Management LLC increased its holdings in shares of Celcuity by 5.2% during the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company's stock valued at $198,000 after purchasing an additional 734 shares during the period. BNP Paribas Financial Markets increased its stake in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after buying an additional 1,167 shares during the period. GAMMA Investing LLC increased its stake in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after buying an additional 1,225 shares during the period. Finally, Tema Etfs LLC increased its stake in Celcuity by 8.9% during the 2nd quarter. Tema Etfs LLC now owns 17,011 shares of the company's stock valued at $227,000 after buying an additional 1,392 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Read More

• Five stocks we like better than Celcuity
• Using the MarketBeat Dividend Yield Calculator
• 3 Overlooked Value Stocks Set to Surge as Rates Drop
• Best Stocks Under $5.00
• Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
• What is the NASDAQ Stock Exchange?
• After the Fed's Rate Cut, PNC Could See a Mortgage Refinance Boom

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Celcuity Right Now?

Before you consider Celcuity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.

While Celcuity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here